- Oops!Something went wrong.Please try again later.
Nu-Med Plus’s Proprietary Technology is designed to open new patient markets by providing treatment options in remote and rural areas with a unique product for the generation of Nitric Oxide that has the capability to rapidly deliver the gas when serious and instantaneous use is needed.
SALT LAKE CITY, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (NUMD), National Investment Bankers Association (NIBA) presenter Nu-Med Plus, Inc., a medical device development company announced that a patent has been filed for a nitric oxide delivery device that is designed for single or short-term use.
Nitric oxide delivery devices on the market today are large, electronically complex devices that are used primarily in neonatal intensive care units. Nu-Med Plus Inc realized that to extend the utility of nitric oxide delivery to a wider range of patients that could benefit from the therapy that another form factor was needed. The result was a simple mechanical device that delivers the appropriate dose of nitric oxide gas per inhalation to the patient. It is handheld with no electronics and a variable nitric oxide dose. A patent was filed in 2019 adding this to the stable of Nu-Med intellectual property. Dr. Craig Morrison, a member of the medical supervisory board of Nu-Med remarked, “It’s a very simple device; it is used like an inhaler. One use that comes to mind is altitude sickness when the user could carry a small disposable unit to use until they could be transported to a lower altitude. Remote areas and rural areas without electrical power, patients being transferred by ambulance, patients being transported for chronic routine treatments and patients in developing countries without access to electric power are generally groups which would need disposable delivery sources of nitric oxide therapy. This could be a real game changer.”
With this new device, Nu-Med Plus will in the future seek enrollment in further studies to investigate its efficacy. Nu-Med Plus is currently in the process of submitting for FDA approval for a nitric oxide delivery system which is a fixed hospital unit. Nu-Med Plus’s technology is designed to be utilized for a variety of inhaled nitric oxide treatments. Inhaled nitric oxide has been proven to stabilize blood pressure, open airways, fight infections and blood clots, combat aging and treat erectile dysfunction.
Media Contact Jeff@nu-medplus.com
Additional details about the National Investment Banking Association’s 147th Investment Conference, Nov. 12-13, 2019, in New York City can be found at: https://nibanet.org/conferences/niba-november-12-13-2019-new-york-ny-conference.
About Nu-Med Plus, Inc.: Nu-Med Plus, Inc. founded in 2011, is a medical device development company created to explore medical applications of newly developed nitric oxide technologies. The strategy focuses on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development have been in the delivery of inhaled nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com. Follow Nu-Med Plus on Twitter and LinkedIn for the latest news.
Forward-Looking Statements: Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.